Licensing GEMS™

iO BiO’s technology is ideally suited to work with your universal cell line and make it a plug and play system for the effector cells allowing the integration of the CAR and or other donor genes.

• Adaptable to Multiple, Boolean, CARs
• Guided editing avoiding off-target insertion
• Independent and/or Dependent Intracellular Signaling
• Uses standard, virus-free, gene editing methods
• Create new CAR cell lines in your universal cell within TWO weeks.
• Potential to save Months in time and Millions of dollars by eliminating viral vectors.

IO BiO’s technology converts any mammalian cell line used for protein secretion in biomanufacturing into a plug and play producer system with only GOI as variable.

• Allows for optimization of producer cell line
• Enhance manufacturing of cell and biomolecules
• Adaptable to single or multiple donor genes
• Precision Editing via CRISPR or alternatives
• Save months of RCB development time.
• Go straight to clone selection, no viral vectors, no cell pools.

GEMS™ directed gene-editing affords cell therapy and biomanufacturing companies with new opportunities. Rather than finding editing opportunities in the existing genome GEMS™ create editing opportunities in a controlled, directed, gene-editing, virus-free, plug-and-play manufacturing system. The established GEMS™  modified cell source can be used over and over again to create new Cell Therapy assets or Protein producing cell line.

iO BiO will out-license the GEMS™ technology and convert customers universal therapeutic cell lines or protein manufacturing cell lines into plug-and-play, streamlined, manufacturing systems for rapid product portfolio development. iO BiO will create customer’s GEMS™ cell lines and inserts the GOI. The modified cell clones will be delivered to the customer or CDMO for expansion.